Biotricity Selected as Finalist in Fast Company's 2021 World Changing Ideas Awards
Biotricity (OTCQB:BTCY) announced that its Biotres device is a finalist in Fast Company's 2021 World Changing Ideas Awards. This recognition reflects the company's commitment to innovation in healthcare technology. Dr. Waqaas Al-Siddiq, CEO, emphasized the device's potential to enhance cardiac diagnostics by providing timely patient insights for better detection and diagnosis of heart conditions. The awards program selected 400 finalists from over 4,000 entries, underscoring Biotricity’s innovative efforts in improving healthcare quality and patient compliance.
- Biotres recognized as a finalist in Fast Company's 2021 World Changing Ideas Awards.
- Potential for Biotres to enhance cardiac diagnostics and improve patient care.
- Selection highlights Biotricity's innovation and dedication to solving healthcare challenges.
- None.
REDWOOD CITY, CA / ACCESSWIRE / May 4, 2021 / Biotricity, Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it's Biotres device is a finalist in Fast Company's 2021 World Changing Ideas. The World Changing Ideas Awards is a yearly award that honors businesses and projects that are committed to pursuing innovation to solve global issues.
"It is an honor to have Biotres selected as a finalist for World Changing Ideas Awards by Fast Company given the considerable competition and number of entries this year," said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. "We consider this recognition a true testament to the hard work and passion of the Biotricity team and, more importantly, the meaningful impact our remote patient monitoring device is expected to have."
Biotricity's upcoming Biotres device was developed to solve the challenges with traditional holter devices that have historically been the standard of care for cardiac diagnostics across the globe. The company identified each issue before developing a comprehensive solution. This was one of the critical factors that led to the Biotres being selected as a finalist in the health category of Fast Company's 2021 World Changing Ideas Awards.
"Doctors and patients are eager for solutions that help them harness the power of data to drive better care and value," said Al-Siddiq. "We designed the Biotres to meet this need by bringing patient-specific insights into a physician's workflow faster, enabling cardiologists to better detect and diagnose heart conditions. With earlier detection and diagnosis, effective at-home use, and workflow integration for physicians, Biotres is expected to positively impact health care quality and patient compliance."
Now in its fifth year, the World Changing Ideas Awards showcases some of the world's most inventive entrepreneurs and companies tackling exigent global challenges. A panel of eminent editors and reporters select 400 finalists from a pool of more than 4,000 entries from across the globe. World Changing Ideas is one of Fast Company's major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better. A panel of judges from across sectors choose finalists based on feasibility and potential for impact. With the goals of awarding ingenuity and fostering innovation, Fast Company draws attention to ideas with great potential and helps them expand their reach to inspire more people to start work on solving important problems that affect us all.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements, including but not limited to the Company's guidance with respect to its fiscal year ended financial results and its financial expectations for future quarters. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release. There cannot be any assurance that the Company will win any award.
CONTACTS:
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
Todd Kehrli or Mark Forney
MKR Investor Relations, Inc.
btcy@mkr-group.com
SOURCE: Biotricity, Inc.
View source version on accesswire.com:
https://www.accesswire.com/644245/Biotricity-Selected-as-Finalist-in-Fast-Companys-2021-World-Changing-Ideas-Awards
FAQ
What is the Biotres device by Biotricity?
What recognition has Biotricity received for Biotres?
When was the Biotres device announced as a finalist?
How many entries were considered for the World Changing Ideas Awards?
What is the stock symbol for Biotricity?
